Eupraxia Pharmaceuticals Inc.
EPRX
$8.08
-$0.17-2.06%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.84M | 18.61M | 17.10M | 12.41M | 12.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.11M | 47.27M | 38.43M | 29.75M | 29.14M |
| Operating Income | -57.11M | -47.27M | -38.43M | -29.75M | -29.14M |
| Income Before Tax | -50.18M | -44.46M | -38.59M | -29.41M | -29.03M |
| Income Tax Expenses | 55.00K | 30.20K | 19.10K | 9.60K | 10.20K |
| Earnings from Continuing Operations | -50.24 | -44.49 | -38.61 | -29.42 | -29.04 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 26.00K | 26.30K | 29.60K | 42.90K | 82.90K |
| Net Income | -50.21M | -44.47M | -38.58M | -29.37M | -28.96M |
| EBIT | -57.11M | -47.27M | -38.43M | -29.75M | -29.14M |
| EBITDA | -56.87M | -47.07M | -38.27M | -29.60M | -29.01M |
| EPS Basic | -0.99 | -1.02 | -1.00 | -0.88 | -0.86 |
| Normalized Basic EPS | -0.59 | -0.60 | -0.58 | -0.51 | -0.51 |
| EPS Diluted | -0.99 | -1.02 | -1.00 | -0.88 | -0.86 |
| Normalized Diluted EPS | -0.59 | -0.60 | -0.58 | -0.51 | -0.51 |
| Average Basic Shares Outstanding | 211.15M | 180.84M | 159.81M | 144.15M | 142.86M |
| Average Diluted Shares Outstanding | 211.15M | 180.84M | 159.81M | 144.15M | 142.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |